GSK (GSK) stock is in focus as the company wins FDA nod for Lynavoy, the first U.S. treatment for cholestatic pruritus in ...

March ⁠19 (Reuters) - ⁠The U.S. ⁠Food and ​Drug ‌Administration approved ‌GSK's ⁠drug for ⁠severe relentless itching ​caused ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

Maggie Hassan. The setup forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid rebates, the report says.

After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial ...

The latest announcement is out from GlaxoSmithKline ( (GSK) ).

GSK said on Thursday that the US Food and Drug Administration has approved its drug ‘Lynavoy’, or linerixibat, for the ...

Health secretary Wes Streeting is considering expanding the existing schedule to age groups beyond infants, such as teenagers.

The US regulator confirmed approval of IBAT inhibitor linerixibat, under the Lynavoy trade name, as a treatment for cholestatic pruritus in PBC on 17th March. PBC is a chronic, progressive autoimmune ...

According to TipRanks, Gordon CFA is a 3-star analyst with an average return of 5.3% and a 48.28% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...